(Press-News.org) Euthymics Bioscience, Inc. today will present Phase II clinical data demonstrating that its lead product candidate EB-1010, a next-generation antidepressant, is effective for treating major depressive disorder (MDD) based on multiple standard measures of outcome for depression. EB-1010 also improved measures of anhedonia, a hallmark symptom of MDD, which is characterized by the inability to experience pleasure. The data further demonstrate that EB-1010 is well tolerated, without the weight gain or sexual dysfunction associated with the most common pharmacological treatments for depression. The data are being presented at the 49th annual meeting of the American College of Neuropsychopharmacology (ACNP) in Miami, Florida.
Euthymics' EB-1010 is a novel unbalanced triple reuptake inhibitor antidepressant intended for patients with MDD who do not respond adequately to selective serotonin reuptake inhibitors (SSRIs), a class which comprises the most common medications in the antidepressant market, which is currently valued at nearly $20 billion worldwide, according to IMS. However, a large subset of patients with major depression - about 66% - do not experience remission after an adequate initial treatment with SSRIs, according to the STAR*D study, a large seven-year study sponsored by the National Institutes of Mental Health. STAR*D also showed that outcomes improved when patients were treated with multiple medications to modulate the key monoamines associated with depression, namely, serotonin, norepinephrine and dopamine. EB-1010 replicates this triple profile in a single medication.
"These data represent convincing Phase II proof-of-concept efficacy for EB-1010 in MDD. More importantly, they validate the potential of a unique unbalanced triple reuptake inhibition profile to treat a large segment of MDD patients with significant unmet medical need," said Pierre V. Trân, M.D., Euthymics Chief Medical Officer, and lead author on the presentation. "These results clearly support further development of EB-1010."
As an unbalanced triple reuptake inhibitor, EB-1010 demonstrates greatest affinity for the transporters that inhibit serotonin reuptake, half as much against norepinephrine reuptake and one-eighth as much against dopamine reuptake, resulting in a ratio of 1:2:8. Balanced triples have equal affinity for the three monoamines, but have not demonstrated efficacy in depression, which makes these data even more striking.
The data presented are from a multicenter, randomized, placebo-controlled, double-blind, six-week study in patients with major depressive disorder (MDD). Sixty-three patients in the U.S. and in Eastern Europe were randomized, and 56 patients were included in the modified intent-to-treat population (MITT) at a titrated dose of 50 mg/day for two weeks and then 100 mg/day for the remaining four weeks. Efficacy results were "statistically significantly" superior when compared to placebo on the primary outcome measure, the Montgomery-Åsberg Depression Rating Scale (MADRS, 18.16 vs. 21.99; p=0.028). Secondary measures including the Clinical Global Impression-Improvement (CGI-I) scale, compared to placebo (p=0.03) as well as anhedonia factor scores derived from the MADRS (p=0.049), were also improved. The safety evaluation showed a benign adverse event profile with no marked difference between EB-1010 and placebo. EB-1010 did not cause a loss in sexual function over the course of the trial and the study indicated a weight-neutral profile.
"Using treatment effect analysis to compare among antidepressants, EB-1010 achieved roughly double the efficacy of SSRIs with a Cohen's d of -0.63 without the side effects associated with first-line treatments for depression," said Anthony A. McKinney, President and CEO of Euthymics. "These data, when carefully analyzed, were so compelling they supported our ability to close a $24 million Series A financing, which we anticipate will be sufficient to fund a major Phase II/III trial to commence in spring 2011."
Euthymics plans to initiate TRIADE (Triple Reuptake Inhibitor Anti-Depressant Effects), a large multicenter Phase II/III clinical trial of EB-1010 in major depression in the first half of 2011. Maurizio Fava, M.D., Professor of Psychiatry at Harvard Medical School and Executive Vice Chair of the Department of Psychiatry at Massachusetts General Hospital will serve as principal investigator for TRIADE.
A second presentation at the ACNP meeting reviewed the preclinical pharmacology of EB-1010 including its inhibition of serotonin, norepinephrine and dopamine uptake transporters. The addition of dopamine to SSRIs has been shown to improve many symptoms of depression that are poorly treated by SSRIs alone. These poorly treated symptoms of depression include cognitive impairment, anhedonia, fatigue and sleepiness. Dopamine neurotransmission also diminishes troublesome effects of many current treatments including sexual dysfunction and weight gain. Dopamine likely plays an important role in the preservation of sexual function as well as the improvement in the ability to perceive pleasure (anhedonia).
INFORMATION:
About Euthymics Bioscience, Inc.
Euthymics Bioscience, Inc. is a neuroscience-focused clinical-stage company developing next-generation treatments for central nervous system disorders. The company's lead product candidate, EB-1010 for depression, is a triple reuptake inhibitor that acts on serotonin, norepinephrine and dopamine in a specific unbalanced ratio and is given as monotherapy (a single capsule). EB-1010 has demonstrated proof-of-concept efficacy as treatment for major depression without causing weight gain or loss of sexual function, which often lead to poor adherence to standard antidepressants.
Euthymics also plans to develop a second triple reuptake inhibitor, EB-1020, which is in the late research stage, for adult ADHD and neuropathic pain.
Euthymics is a private corporation with headquarters in Cambridge, Massachusetts. Additional information can be found on the company's website at www.euthymics.com.
Computer scientists have analysed over a million news articles in 22 languages to pinpoint what factors, such as the Eurovision song contest, influence and shape the news agenda in 27 EU countries. This is the first large-scale content-analysis of cross-linguistic text using artificial intelligence techniques.
Every day hundreds of news outlets across Europe choose which story to cover from a wide and diverse selection. While each outlet may be making these choices based on individual criteria, clear patterns emerge when all these choices are studied over a large set ...
A study of chimpanzees has revealed that dominant animals with higher testosterone levels tend to suffer from an increased burden of parasites. Researchers writing in BioMed Central's open access journal BioPsychoSocial Medicine observed the primates' behavior and studied their droppings to draw the link between dominance and infection status.
Michael Muehlenbein from Indiana University and David Watts from Yale University, USA, carried out the study in 22 male animals at Kibale National Park, Uganda. According to Muehlenbein, "Acquisition and maintenance of high dominance ...
Brussels, 9 December 2010 - Europe needs new particle accelerators and major upgrades to existing facilities over the next ten years to stay at the forefront of nuclear physics, according to the European Science Foundation (ESF), which launches its 'Long Range Plan 2010' for nuclear physics today.
Nuclear physicists are working to understand the origin, evolution and nature of matter that constitutes nearly 100 per cent of visible matter in the universe. As the home of GANIL, GSI, CERN and a wide network of closely collaborating facilities, Europe is world-leader in ...
A new study identifies a previously unrecognized mutation that causes an inherited form of amyotrophic lateral sclerosis (ALS). The research, published by Cell Press in the December 9th issue of the journal Neuron, implicates defects in a cellular pathway linked with degradation of unwanted proteins in the underlying pathology of ALS and provides new insight into this incurable and fatal neurodegenerative disease.
ALS, also known as Lou Gehrig's disease, is a devastating disease that causes destruction of the neurons in the brain and spinal cord that control voluntary ...
A new study uncovers a mechanism linking a specific type of cellular stress with brain damage similar to that associated with neurodegenerative disease. The research, published by Cell Press in the December 9 issue of the journal Neuron, is the first to highlight the significance of the reduction of a specific calcium signal that is directly tied to cell fate.
Body cells are constantly exposed to various environmental stresses. Although cells possess some natural defenses, excessive stress can lead to a type of cell death called apoptosis. "It is thought that excessive ...
ITHACA, N.Y. – Comparing the locations of photos posted on the Internet with social network contacts, Cornell University computer scientists have found that as few as three "co-locations" for images at different times and places could predict with high probability that two people posting photos were socially connected.
The results have implications for online privacy, the researchers said, but also suggest a quantitative answer to a very old psychological question: What can we conclude from observing coincidences?
"This is a kind of question that goes way back," said ...
Yale University researchers have found that a single molecule not only connects brain cells but also changes how we learn. The findings, reported in the December 9 issue of the journal Neuron, may help researchers discover ways to improve memory and could lead to new therapies to correct neurological disorders.
The junctions between brain cells over which nerve pulses pass — called synapses — are crucial for regulating learning and memory and how we think. Aberrations in the structure and function of synapses have been linked to mental retardation and autism, while synapses ...
A group of researchers at MIT, Cornell University and University College London have used one of the world's largest databases of telecommunications records to redraw the map of Great Britain. The research, which will be published in the journal PLoS ONE on Dec. 8, is based on the analysis of 12 billion anonymized records representing more than 95% of Great Britain's residential and business landlines.
"Since the pioneering work of Christaller and Lösch in the early 20th century, a long-standing question in economic geography has been how to define regions in space," ...
PULLMAN, Wash.—Beverages supplemented by whey-based protein can significantly reduce elevated blood pressure, reducing the risk of stroke and heart disease, a Washington State University study has found.
Research led by nutritional biochemist Susan Fluegel and published in International Dairy Journal found that daily doses of commonly available whey brought a more than six-point reduction in the average blood pressure of men and women with elevated systolic and diastolic blood pressures. While the study was confined to 71 student subjects between the ages of 18 and 26, ...
Prostate cancer is the most common type of cancer among men, but its diagnosis has up to now been inaccurate and unpleasant. Researchers at Eindhoven University of Technology (TU/e), in cooperation with AMC Amsterdam, have developed an imaging technology that can accurately identify tumors. The technology is based on ultrasound, and also has the potential to assess how aggressive tumors are. This can lead to better and more appropriate treatment, and to cost savings in health care.
About 11% of men who die of cancer in the western world do so as a result of prostate cancer. ...
